Project Grant K99CA296774
Award Date
7/1/25
Completion Date
6/30/27
Dollars Obligated
$176K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $693,781 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct research aimed at improving treatments for cancers with mutations in the IDH1 gene. The key goals of this 5-year project are to: Further understand how mutant IDH1 drives cancer growth and how IDH1 inhibitor drugs work to block cancer progression, including investigating...
This Project Grant award of $662,516 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will support research by The General Hospital Corporation (doing business as Massachusetts General Hospital) to investigate how fractionated radiation therapy affects the tumor microenvironment and influences drug delivery for more effective chemoradiotherapy. The project aims to: 1) quantify how local radiation reshapes the tumor microenvironment to impact passive drug delivery in...
The National Institute of General Medical Sciences (NIGMS) awarded a $453,750 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), for the project "Revealing the Crosstalk Between One Carbon Metabolism, SAM Availability and Chromatin Methylation". This 5-year grant, effective June 1, 2025, will support MGH's innovative research investigating how cellular...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $654,197 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct research on pancreatic cancer patient-derived xenograft (PDX) tumor models. The research aims to: Define the molecular subtypes of pancreatic ductal adenocarcinoma (PDAC) that respond to standard-of-care chemotherapies like FOLFIRINOX and gemcitabine + Abraxane. Elucidate how...
This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $140,130 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to elucidate the role of thiol reductive stress in lung cancer growth and metastasis. The award supports research investigating how activation of the NRF2 transcriptional regulator disrupts the NADH/NAD+ equilibrium, inducing reductive stress that blocks mitochondrial function and inhibits...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $623,120 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to research new chemical "degrader" tools that target chromatin regulators critical for the survival and proliferation of multiple myeloma cells. The project aims to investigate the mechanisms of CBP and P300 degradation in myeloma and credential these new chemical tools as candidates...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $544,478 to The University of Texas Southwestern Medical Center to conduct research on "Decoding the Metabolic Routes of Purine Nucleotides in Cancer". The overarching goal is to expand the mechanistic understanding of purine synthesis pathways in tumors and identify new strategies to target purine supply mechanisms for effective cancer treatment. Key research aims include:...
This federal Project Grant award of $661,831 from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) supports the creation of the Human Cancer Metabolome Atlas (HCMA). The goal is to establish a comprehensive, open-access database of metabolomics data from over 2,000 patient-derived tumor samples. This resource will enable researchers to better understand the role of tumor metabolism in cancer biology and inform the development of...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Biology Research program (CFDA 93.396), provides $698,008 to The Trustees of the University of Pennsylvania to conduct research on the regulation of histone propionylation in pancreatic ductal adenocarcinoma (PDA). The project aims to elucidate the mechanism by which branched-chain amino acid metabolism generates nuclear propionyl-CoA to modulate histone propionylation and gene expression, with the goal...
The Project Grant award R35CA293978, provided by the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research), supports research to identify the mechanisms driving rapid evolution of cancer genomes. The $942,442 award to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, MA will fund investigations into two catastrophic mutational processes in cancer, chromothripsis and chromoplexy. The research aims to better understand the mechanisms of chromosome fragmentation, DNA...